Form 4: Illumina's VP, Chief Accounting Officer, Scott D. Ericksen, Reports Acquisition and Disposal of Common Stock and Performance Shares

Scott D. Ericksen, VP, Chief Accounting Officer of Illumina, Inc., reports the acquisition of common stock and performance shares, along with the disposal of common stock, as per a recent SEC Form 4 filing.

Summary

• On March 5, 2025, Scott D. Ericksen, VP, Chief Accounting Officer of Illumina, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 4,435 shares of common stock at $0 and the disposal of 13,692 shares of common stock.
• Additionally, Ericksen acquired 2,218 performance shares tied to the company's three-year average operating margin for fiscal years 2025-2027, vesting on January 2, 2028.
• He also acquired 2,218 performance shares linked to Illumina's relative total shareholder return for the fiscal year ending January 2, 2028.
• The number of shares issued for both performance share grants will range from 0% to 250% of the specified amount, based on the company's performance relative to pre-defined objectives, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions by an executive, with no explicit positive or negative implications. The performance-based compensation suggests a positive outlook if the company meets its targets.

Positives

• The acquisition of performance shares aligns the executive's interests with the company's long-term performance, specifically operating margin and shareholder return.

Risks

• The value of the performance shares is contingent on Illumina achieving specific operating margin and shareholder return targets, which may not be met.
• The executive must remain a service provider until the vesting dates to receive the performance shares.

Future Outlook

The executive's future compensation is tied to the company's performance through performance-based stock units, incentivizing improved operating margin and shareholder return.

Industry Context

Executive compensation packages often include performance-based equity to align management's interests with those of shareholders, a common practice in the biotechnology industry.

Comparison to Industry Standards

• Illumina's use of performance-based stock units is consistent with compensation practices at peer companies like Thermo Fisher Scientific and Danaher, which also utilize similar metrics to incentivize executives.
• The vesting schedules and performance targets are likely benchmarked against industry standards to ensure competitiveness and alignment with shareholder value creation.

Stakeholder Impact

• The acquisition of performance shares aligns the executive's interests with those of shareholders, potentially leading to decisions that benefit shareholder value.
• The vesting of restricted stock units is subject to awardee's continuing status as a service provider on such dates.

Key Dates